Form 4: Madrigal Pharmaceuticals Director James M. Daly Receives Stock and Option Grants

Director James M. Daly of Madrigal Pharmaceuticals received restricted stock units and stock options on June 25, 2024, according to a Form 4 filing.

Summary

• James M. Daly, a director at Madrigal Pharmaceuticals, was granted 714 restricted stock units and options to purchase 1,105 shares of common stock on June 25, 2024.
• The restricted stock units vest on June 25, 2025, contingent upon continued service with the issuer.
• The stock options vest 100% on the first anniversary of the grant date, also contingent upon continued service as a director.
• Following these transactions, Daly directly owns 1,912 shares of common stock and options to purchase 1,105 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document reflects standard compensation practices, indicating confidence in the director's continued service and contribution to the company.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting conditions of the granted securities.

Industry Context

Stock and option grants are a common form of executive compensation in the pharmaceutical industry, aligning management and board member interests with shareholder value.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedules (one year for options and restricted stock units) are typical for such grants.
• Comparable companies like Viking Therapeutics or Intercept Pharmaceuticals also utilize stock options and restricted stock units as part of their director compensation packages.

Stakeholder Impact

• The grants incentivize the director to act in the best interests of shareholders.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates